Company news

Protara Therapeutics, Inc. news in 2020

Protara Therapeutics, Inc.'s news releases, calls and decks from 2020, newest first.

View company

Protara Therapeutics Announces Promotion of Jacqueline Zummo, Ph.D., to Chief Scientific Operations Officer

December 6, 2020

Protara Therapeutics Announces Third Quarter 2020 Financial Results and Business Overview

November 11, 2020

Protara Therapeutics Announces Pricing of $147.6 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred Stock

September 21, 2020

Protara Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock

September 20, 2020

Protara Therapeutics Provides Comparability and U.S. Regulatory Updates for TARA-002 Supporting Advancement in Oncology and Rare Disease Indications

September 7, 2020

Protara Therapeutics Announces Second Quarter 2020 Financial Results and Business Overview

August 2, 2020

Protara Therapeutics Receives Rare Pediatric Disease Designation for TARA-002 for the Treatment of Lymphatic Malformations

July 27, 2020

Protara Therapeutics Announces Appointment of Barry P. Flannelly to Board of Directors

July 23, 2020

Protara Therapeutics Receives Fast Track Designation from U.S. FDA for Intravenous Choline Chloride for the Treatment of Intestinal Failure Associated Liver Disease

May 25, 2020

Protara Therapeutics Announces First Quarter 2020 Financial Results and Business Overview

May 12, 2020

ArTara Therapeutics Announces Corporate Name Change to Protara Therapeutics

May 10, 2020

ArTara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 1, 2020

ArTara Therapeutics Appoints Blaine Davis as Chief Financial Officer

February 10, 2020

Decks in 2020